Dr. Bina Keshavan is an accomplished biopharmaceutical leader with more than two decades of drug development experience, including over a decade of managing the development of rare disease products. Her career achievements include establishing and leading the program leadership and management across several large and small biopharmaceutical companies focused on rare and large indications, biologics, small molecules, cell and gene therapies for early and late-stage product development. Most recently, Dr. Bina Keshavan established the program and portfolio management at Ovid Therapeutics, thereby improving strategic decision-making. Additionally, Dr. Bina Keshavan has excelled in biologics license applications, product launches, and drug life-cycle management.
Since 2022, Dr. Bina Keshavan has served as a principal consultant to a diverse set of biopharmaceutical industry clients. She assists these organizations with program leadership and product strategy, with an emphasis on mid- and late-stage neurological, genetic, and metabolic disorder programs. She drove operations at Ovid Therapeutics as the vice president and head of program and portfolio management, preceded by senior director roles at Shire Pharmaceuticals and Biogen, Inc.
Dr. Bina Keshavan holds a doctor of philosophy in neuroscience from Dalhousie University. When she is not supporting clients with biopharmaceutical program development, she enjoys international travel.